SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more
SCHOTT Pharma AG & Co. KGaA (1SXP) - Total Liabilities
Latest total liabilities as of September 2024: €650.00 Million EUR
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) has total liabilities worth €650.00 Million EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SCHOTT Pharma AG & Co. KGaA - Total Liabilities Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Liabilities
The table below lists competitors of SCHOTT Pharma AG & Co. KGaA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Obsidian Energy Ltd
NYSE MKT:OBE
|
USA | $400.30 Million |
|
Wowprime Corp
TW:2727
|
Taiwan | NT$10.89 Billion |
|
Shenzhen WOTE Advanced Materials Co Ltd
SHE:002886
|
China | CN¥1.98 Billion |
|
COFCO Joycome Foods Limited
F:0M7
|
Germany | €11.25 Billion |
|
Lee and Man Paper Manufacturing Limited
F:LMP
|
Germany | €26.93 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥797.08 Million |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥877.24 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down SCHOTT Pharma AG & Co. KGaA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCHOTT Pharma AG & Co. KGaA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total liabilities of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €650.00 Million | +20.45% |
| 2023-06-30 | €539.65 Million | +10.71% |
| 2022-06-30 | €487.46 Million | +52.10% |
| 2021-06-30 | €320.48 Million | +14.31% |
| 2020-06-30 | €280.36 Million | -- |